APD791 is an oral anti-thrombotic drug candidate being evaluated in a Phase 1 clinical trial by Arena. APD791 is intended to lower the risk of arterial thrombosis by reducing the amplification of platelet aggregation, arterial constriction and intimal hyperplasia mediated by serotonin.
Fitur visualisasi ini dikembangkan menggunakan pendekatan Graph Theory untuk memetakan hubungan polifarmasi dan molekuler. Entitas (Obat, Target, Gen) direpresentasikan sebagai Simpul (Nodes), sedangkan hubungan biologisnya sebagai Sisi (Edges).
drugbank-id dan name pada skema XML DrugBank.targets/target yang memuat polipeptida sasaran.gene-name dan varian snp-effects.Tata letak grafik menggunakan algoritma Force-Directed Graph (Barnes-Hut). Model fisika ini menerapkan gaya tolak-menolak antar simpul (Gravitasi: -3000) agar tidak tumpang tindih, serta gaya pegas (Spring: 0.04) pada garis penghubung untuk fleksibilitas interaksi.
| Buprenorphine | APD791 may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine. |
| Doxylamine | Doxylamine may increase the central nervous system depressant (CNS depressant) activities of APD791. |
| Dronabinol | Dronabinol may increase the central nervous system depressant (CNS depressant) activities of APD791. |
| Droperidol | Droperidol may increase the central nervous system depressant (CNS depressant) activities of APD791. |
| Hydrocodone | APD791 may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone. |
| Hydroxyzine | Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of APD791. |
| Magnesium sulfate | The therapeutic efficacy of APD791 can be increased when used in combination with Magnesium sulfate. |
| Methotrimeprazine | APD791 may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine. |
| Metyrosine | APD791 may increase the sedative activities of Metyrosine. |
| Minocycline | Minocycline may increase the central nervous system depressant (CNS depressant) activities of APD791. |
| Mirtazapine | APD791 may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine. |
| Nabilone | Nabilone may increase the central nervous system depressant (CNS depressant) activities of APD791. |
| Orphenadrine | APD791 may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine. |
| Paraldehyde | APD791 may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde. |
| Perampanel | Perampanel may increase the central nervous system depressant (CNS depressant) activities of APD791. |
| Pramipexole | APD791 may increase the sedative activities of Pramipexole. |
| Ropinirole | APD791 may increase the sedative activities of Ropinirole. |
| Rotigotine | APD791 may increase the sedative activities of Rotigotine. |
| Rufinamide | The risk or severity of adverse effects can be increased when Rufinamide is combined with APD791. |
| Sodium oxybate | APD791 may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate. |
| Suvorexant | APD791 may increase the central nervous system depressant (CNS depressant) activities of Suvorexant. |
| Tapentadol | Tapentadol may increase the central nervous system depressant (CNS depressant) activities of APD791. |
| Thalidomide | APD791 may increase the central nervous system depressant (CNS depressant) activities of Thalidomide. |
| Zolpidem | APD791 may increase the central nervous system depressant (CNS depressant) activities of Zolpidem. |
| Methadone | The risk or severity of adverse effects can be increased when Methadone is combined with APD791. |
| Dicoumarol | The risk or severity of adverse effects can be increased when APD791 is combined with Dicoumarol. |
| Phenindione | The risk or severity of adverse effects can be increased when APD791 is combined with Phenindione. |
| Warfarin | The risk or severity of adverse effects can be increased when APD791 is combined with Warfarin. |
| Phenprocoumon | The risk or severity of adverse effects can be increased when APD791 is combined with Phenprocoumon. |
| Acenocoumarol | The risk or severity of adverse effects can be increased when APD791 is combined with Acenocoumarol. |
| 4-hydroxycoumarin | The risk or severity of adverse effects can be increased when APD791 is combined with 4-hydroxycoumarin. |
| Coumarin | The risk or severity of adverse effects can be increased when APD791 is combined with Coumarin. |
| (R)-warfarin | The risk or severity of adverse effects can be increased when APD791 is combined with (R)-warfarin. |
| Ethyl biscoumacetate | The risk or severity of adverse effects can be increased when APD791 is combined with Ethyl biscoumacetate. |
| Fluindione | The risk or severity of adverse effects can be increased when APD791 is combined with Fluindione. |
| Clorindione | The risk or severity of adverse effects can be increased when APD791 is combined with Clorindione. |
| Diphenadione | The risk or severity of adverse effects can be increased when APD791 is combined with Diphenadione. |
| Tioclomarol | The risk or severity of adverse effects can be increased when APD791 is combined with Tioclomarol. |
| (S)-Warfarin | The risk or severity of adverse effects can be increased when APD791 is combined with (S)-Warfarin. |
| Ethanol | APD791 may increase the central nervous system depressant (CNS depressant) activities of Ethanol. |
| Azelastine | APD791 may increase the central nervous system depressant (CNS depressant) activities of Azelastine. |
| Brimonidine | Brimonidine may increase the central nervous system depressant (CNS depressant) activities of APD791. |
| Fluvoxamine | The risk or severity of adverse effects can be increased when APD791 is combined with Fluvoxamine. |
| Citalopram | The risk or severity of adverse effects can be increased when APD791 is combined with Citalopram. |
| Duloxetine | The risk or severity of adverse effects can be increased when APD791 is combined with Duloxetine. |
| Trazodone | The risk or severity of adverse effects can be increased when APD791 is combined with Trazodone. |
| Paroxetine | The risk or severity of adverse effects can be increased when APD791 is combined with Paroxetine. |
| Sertraline | The risk or severity of adverse effects can be increased when APD791 is combined with Sertraline. |
| Sibutramine | The risk or severity of adverse effects can be increased when APD791 is combined with Sibutramine. |
| Nefazodone | The risk or severity of adverse effects can be increased when APD791 is combined with Nefazodone. |
| Escitalopram | The risk or severity of adverse effects can be increased when APD791 is combined with Escitalopram. |
| Zimelidine | The risk or severity of adverse effects can be increased when APD791 is combined with Zimelidine. |
| Dapoxetine | The risk or severity of adverse effects can be increased when APD791 is combined with Dapoxetine. |
| Milnacipran | The risk or severity of adverse effects can be increased when APD791 is combined with Milnacipran. |
| Desvenlafaxine | The risk or severity of adverse effects can be increased when APD791 is combined with Desvenlafaxine. |
| Seproxetine | The risk or severity of adverse effects can be increased when APD791 is combined with Seproxetine. |
| Indalpine | The risk or severity of adverse effects can be increased when APD791 is combined with Indalpine. |
| Ritanserin | The risk or severity of adverse effects can be increased when APD791 is combined with Ritanserin. |
| Alaproclate | The risk or severity of adverse effects can be increased when APD791 is combined with Alaproclate. |
| Zopiclone | The risk or severity of adverse effects can be increased when APD791 is combined with Zopiclone. |
| Botulinum toxin type B | The risk or severity of CNS depression can be increased when Botulinum toxin type B is combined with APD791. |
| Botulinum toxin type A | The risk or severity of CNS depression can be increased when Botulinum toxin type A is combined with APD791. |
| Tryptophan | The risk or severity of CNS depression can be increased when Tryptophan is combined with APD791. |
| Baclofen | Baclofen may increase the central nervous system depressant (CNS depressant) activities of APD791. |
| Lorazepam | The risk or severity of CNS depression can be increased when Lorazepam is combined with APD791. |
| Ethchlorvynol | The risk or severity of CNS depression can be increased when Ethchlorvynol is combined with APD791. |
| Succinylcholine | The risk or severity of CNS depression can be increased when Succinylcholine is combined with APD791. |
| Reserpine | The risk or severity of CNS depression can be increased when Reserpine is combined with APD791. |
| Eletriptan | The risk or severity of CNS depression can be increased when Eletriptan is combined with APD791. |
| Enflurane | The risk or severity of CNS depression can be increased when Enflurane is combined with APD791. |
| Temazepam | The risk or severity of CNS depression can be increased when Temazepam is combined with APD791. |
| Reboxetine | The risk or severity of CNS depression can be increased when Reboxetine is combined with APD791. |
| Butabarbital | The risk or severity of CNS depression can be increased when Butabarbital is combined with APD791. |
| Butalbital | The risk or severity of CNS depression can be increased when Butalbital is combined with APD791. |
| Methysergide | The risk or severity of CNS depression can be increased when Methysergide is combined with APD791. |
| Cabergoline | The risk or severity of CNS depression can be increased when Cabergoline is combined with APD791. |
| Phenytoin | The risk or severity of CNS depression can be increased when Phenytoin is combined with APD791. |
| Topiramate | The risk or severity of CNS depression can be increased when Topiramate is combined with APD791. |
| Clemastine | The risk or severity of CNS depression can be increased when Clemastine is combined with APD791. |
| Venlafaxine | The risk or severity of CNS depression can be increased when Venlafaxine is combined with APD791. |
| Etomidate | The risk or severity of CNS depression can be increased when Etomidate is combined with APD791. |
| Morphine | The risk or severity of CNS depression can be increased when Morphine is combined with APD791. |
| Talbutal | The risk or severity of CNS depression can be increased when Talbutal is combined with APD791. |
| Pentobarbital | The risk or severity of CNS depression can be increased when Pentobarbital is combined with APD791. |
| Valproic acid | The risk or severity of CNS depression can be increased when Valproic acid is combined with APD791. |
| Zolmitriptan | The risk or severity of CNS depression can be increased when Zolmitriptan is combined with APD791. |
| Codeine | The risk or severity of CNS depression can be increased when Codeine is combined with APD791. |
| Dihydroergotamine | The risk or severity of CNS depression can be increased when Dihydroergotamine is combined with APD791. |
| Amitriptyline | The risk or severity of CNS depression can be increased when Amitriptyline is combined with APD791. |
| Tolcapone | The risk or severity of CNS depression can be increased when Tolcapone is combined with APD791. |
| Hydromorphone | The risk or severity of CNS depression can be increased when Hydromorphone is combined with APD791. |
| Olanzapine | The risk or severity of CNS depression can be increased when Olanzapine is combined with APD791. |
| Cetirizine | The risk or severity of CNS depression can be increased when Cetirizine is combined with APD791. |
| Protriptyline | The risk or severity of CNS depression can be increased when Protriptyline is combined with APD791. |
| Trimethadione | The risk or severity of CNS depression can be increased when Trimethadione is combined with APD791. |
| Clobazam | The risk or severity of sedation, somnolence, and CNS depression can be increased when Clobazam is combined with APD791. |
| Chlorzoxazone | The risk or severity of CNS depression can be increased when Chlorzoxazone is combined with APD791. |
| Clozapine | The risk or severity of CNS depression can be increased when Clozapine is combined with APD791. |
| Meprobamate | The risk or severity of CNS depression can be increased when Meprobamate is combined with APD791. |
| Thiethylperazine | The risk or severity of CNS depression can be increased when Thiethylperazine is combined with APD791. |